PURPOSE: In cancer research, outcome measures may co-vary. Treatment and treatment related impairment of health-related quality of life (HRQoL) may affect survival. When these effects are analyzed separately, bias may arise. Therefore, we investigated the combined effect of treatment and longitudinally measured HRQoL on survival. METHODS:Patients with anaplastic oligodendrogliomas (n = 288) who were randomized (EORTC 26951) to radiotherapy (RT) alone or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy were analyzed. HRQoL [appetite loss (AP)] was assessed with the EORTC QLQ-C30. We compared survival results from different analysis strategies: Cox model with treatment only [model 1 (M1)] or with treatment and time-dependent AP score [model 2 (M2)] and the joint model combining longitudinal AP score and survival [model 3 (M3)]. RESULTS: The estimated hazard ratio (HR) for RT plus PCV was 0.76 (95 % CI 0.58-1.00) for M1, 0.72 (0.55-0.96) for M2, and 0.69 (0.52-0.92) for M3. This corresponds to a lower risk of death of 24 % in M1, 28 % in M2, and 31 % in M3, for patients treated with RT plus PCV chemotherapy. AP resulted in an increased risk of death, with estimated HR of 1.06 (1.01-1.12) for M2 and 1.13 (1.03-1.23) for M3: Every 10-point increase of AP resulted in a 13 % increased risk of death in M3 as compared to 6 % in M2. CONCLUSION: Part of the survival benefit of treatment with RT plus PCV chemotherapy can be masked by the negative effect that this treatment has on patients' HRQoL. In our study, up to 7 % of the theoretical treatment efficacy was lost when AP was not adjusted through joint modeling.
RCT Entities:
PURPOSE: In cancer research, outcome measures may co-vary. Treatment and treatment related impairment of health-related quality of life (HRQoL) may affect survival. When these effects are analyzed separately, bias may arise. Therefore, we investigated the combined effect of treatment and longitudinally measured HRQoL on survival. METHODS:Patients with anaplastic oligodendrogliomas (n = 288) who were randomized (EORTC 26951) to radiotherapy (RT) alone or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy were analyzed. HRQoL [appetite loss (AP)] was assessed with the EORTC QLQ-C30. We compared survival results from different analysis strategies: Cox model with treatment only [model 1 (M1)] or with treatment and time-dependent AP score [model 2 (M2)] and the joint model combining longitudinal AP score and survival [model 3 (M3)]. RESULTS: The estimated hazard ratio (HR) for RT plus PCV was 0.76 (95 % CI 0.58-1.00) for M1, 0.72 (0.55-0.96) for M2, and 0.69 (0.52-0.92) for M3. This corresponds to a lower risk of death of 24 % in M1, 28 % in M2, and 31 % in M3, for patients treated with RT plus PCV chemotherapy. AP resulted in an increased risk of death, with estimated HR of 1.06 (1.01-1.12) for M2 and 1.13 (1.03-1.23) for M3: Every 10-point increase of AP resulted in a 13 % increased risk of death in M3 as compared to 6 % in M2. CONCLUSION: Part of the survival benefit of treatment with RT plus PCV chemotherapy can be masked by the negative effect that this treatment has on patients' HRQoL. In our study, up to 7 % of the theoretical treatment efficacy was lost when AP was not adjusted through joint modeling.
Authors: Victor Novack; Jeremy R Beitler; Maayan Yitshak-Sade; B Taylor Thompson; David A Schoenfeld; Gordon Rubenfeld; Daniel Talmor; Samuel M Brown Journal: Crit Care Med Date: 2020-02 Impact factor: 7.598
Authors: Audrey Winter; Benjamin Cuer; Thierry Conroy; Beata Juzyna; Sophie Gourgou; Caroline Mollevi; Célia Touraine Journal: Qual Life Res Date: 2022-09-17 Impact factor: 3.440
Authors: Barbara L Andersen; Joseph P McElroy; David P Carbone; Carolyn J Presley; Rachel M Smith; Peter G Shields; Guy N Brock Journal: Psychosom Med Date: 2022 Feb-Mar 01 Impact factor: 3.864
Authors: Theresa A Lawrie; David Gillespie; Therese Dowswell; Jonathan Evans; Sara Erridge; Luke Vale; Ashleigh Kernohan; Robin Grant Journal: Cochrane Database Syst Rev Date: 2019-08-05
Authors: Amir H Zamanipoor Najafabadi; Marthe C M Peeters; Daniel J Lobatto; Marieke L D Broekman; Timothy R Smith; Nienke R Biermasz; Saskia M Peerdeman; Wilco C Peul; Martin J B Taphoorn; Wouter R van Furth; Linda Dirven Journal: Acta Neurochir (Wien) Date: 2017-09-27 Impact factor: 2.216
Authors: Marijke B Coomans; Marthe C M Peeters; Johan A F Koekkoek; Jan W Schoones; Jaap Reijneveld; Martin J B Taphoorn; Linda Dirven Journal: Cancers (Basel) Date: 2020-11-24 Impact factor: 6.639
Authors: Marijke B Coomans; Linda Dirven; Neil K Aaronson; Brigitta G Baumert; Martin van den Bent; Andrew Bottomley; Alba A Brandes; Olivier Chinot; Corneel Coens; Thierry Gorlia; Ulrich Herrlinger; Florence Keime-Guibert; Annika Malmström; Francesca Martinelli; Jeff A Sloan; Roger Stupp; Andrea Talacchi; Michael Weller; Wolfgang Wick; Jaap C Reijneveld; Martin J B Taphoorn Journal: Neurooncol Adv Date: 2020-10-29